Synopsis
Synopsis
0
VMF
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2 Propylpentanoic Acid
2. 2-propylpentanoic Acid
3. Calcium Valproate
4. Convulsofin
5. Depakene
6. Depakine
7. Depakote
8. Dipropyl Acetate
9. Divalproex
10. Ergenyl
11. Magnesium Valproate
12. Propylisopropylacetic Acid
13. Semisodium Valproate
14. Sodium Valproate
15. Valproate
16. Valproate Calcium
17. Valproate Sodium
18. Valproic Acid
19. Valproic Acid, Sodium Salt (2:1)
20. Vupral
1. 76584-70-8
2. Valproate Semisodium
3. Epival
4. Depakote
5. Sodium Divalproate
6. Semisodium Valproate
7. Sprinkle
8. Abbott 50711
9. Divalproex
10. Valdisoval
11. Valproato Semisodico
12. Delepsine
13. Valcote
14. Valparin
15. Epilex
16. Valproate Semisodique
17. Sodium Hydrogen Divalproate
18. Valproatum Seminatricum
19. Sodium Hydrogen Bis(2-propylpentanoate)
20. Pentanoic Acid, 2-propyl-, Sodium Salt (2:1)
21. Abbott-50711
22. Sodium Hydrogen Bis(2-propylvalerate)
23. Divalproex Sodium [usan:usp]
24. Divalproex (sodium)
25. Sodium;2-propylpentanoate;2-propylpentanoic Acid
26. Valproate Semisodium (inn)
27. Depakote Er
28. Chebi:4667
29. Divalproate
30. Valproic Acid (semisodium Salt)
31. Depakote Cp
32. Valproate Semisodium [inn]
33. Valproate Semisodique [french]
34. Valproato Semisodico [spanish]
35. Valproatum Seminatricum [latin]
36. Valproic Acid Semisodium Salt
37. Depakote (tn)
38. Natrium Hydrogen Bis(2-propylvalerat)
39. Valproic Acid Semisodium Salt (2:1)
40. 644vl95ao6
41. Valproic Acid Sodium Salt (2:1)
42. Divalproex Sodium (usp)
43. Unii-644vl95ao6
44. Sodium Divalproex
45. Sodium Hydrogen Bis(2-propylvalerate), Oligomer
46. Sodium; 2-propylpentanoate; 2-propylpentanoic Acid
47. Schembl40996
48. Chembl2105613
49. Sodium;hydron;2-propylpentanoate
50. Dtxsid70227388
51. Hms3651c17
52. Hms3884o06
53. Bcp12800
54. S1703
55. Sodiumhydrogenbis(2-propylpentanoate)
56. Akos015895200
57. Ccg-267581
58. As-17254
59. Db-056089
60. Ft-0625375
61. Sw219169-1
62. C76453
63. D00304
64. Ab01568255_01
65. A838751
66. Sodium 2-propylpentanoate--2-propylpentanoic Acid (1:1)
Molecular Weight | 310.40 g/mol |
---|---|
Molecular Formula | C16H31NaO4 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 10 |
Exact Mass | 310.21200375 g/mol |
Monoisotopic Mass | 310.21200375 g/mol |
Topological Polar Surface Area | 77.4 Ų |
Heavy Atom Count | 21 |
Formal Charge | 0 |
Complexity | 192 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 6 | |
---|---|
Drug Name | Depakote |
Drug Label | Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralization of valproic acid with 0.5 equivalent of sodium hydroxide. Chemically it is d... |
Active Ingredient | Divalproex sodium |
Dosage Form | Capsule, delayed rel pellets; Tablet, delayed release |
Route | Oral |
Strength | eq 125mg valproic acid; eq 500mg valproic acid; eq 250mg valproic acid |
Market Status | Prescription |
Company | Abbvie |
2 of 6 | |
---|---|
Drug Name | Depakote er |
Drug Label | Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralization of valproic acid with 0.5 equivalent of sodium hydroxide. Chemically it is d... |
Active Ingredient | Divalproex sodium |
Dosage Form | Tablet, extended release |
Route | oral; Oral |
Strength | 250mg; eq 500mg valproic acid; eq 250mg valproic acid; 500mg |
Market Status | Prescription |
Company | Abbott; Abbvie |
3 of 6 | |
---|---|
Drug Name | Divalproex sodium |
Drug Label | Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship. Chemically it is designated as sodium hydrogen bis(2-propylpentanoate). Divalproex sodium has the following structure:Di... |
Active Ingredient | Divalproex sodium |
Dosage Form | Tablet, extended release; Capsule, delayed rel pellets; Tablet, delayed release |
Route | Oral |
Strength | eq 125mg valproic acid; eq 500mg valproic acid; eq 250mg valproic acid |
Market Status | Prescription |
Company | Anchen Pharms; Wockhardt; Upsher Smith; Nu Pharm; Actavis Labs Fl; Teva; Vintage; Aurobindo Pharma; Sun Pharm Inds; Reddys; Lupin; Zydus Pharms Usa; Dr Reddys Labs; Sandoz; Orchid Hlthcare; Mylan; Unichem Labs; Impax Labs |
4 of 6 | |
---|---|
Drug Name | Depakote |
Drug Label | Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralization of valproic acid with 0.5 equivalent of sodium hydroxide. Chemically it is d... |
Active Ingredient | Divalproex sodium |
Dosage Form | Capsule, delayed rel pellets; Tablet, delayed release |
Route | Oral |
Strength | eq 125mg valproic acid; eq 500mg valproic acid; eq 250mg valproic acid |
Market Status | Prescription |
Company | Abbvie |
5 of 6 | |
---|---|
Drug Name | Depakote er |
Drug Label | Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralization of valproic acid with 0.5 equivalent of sodium hydroxide. Chemically it is d... |
Active Ingredient | Divalproex sodium |
Dosage Form | Tablet, extended release |
Route | oral; Oral |
Strength | 250mg; eq 500mg valproic acid; eq 250mg valproic acid; 500mg |
Market Status | Prescription |
Company | Abbott; Abbvie |
6 of 6 | |
---|---|
Drug Name | Divalproex sodium |
Drug Label | Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship. Chemically it is designated as sodium hydrogen bis(2-propylpentanoate). Divalproex sodium has the following structure:Di... |
Active Ingredient | Divalproex sodium |
Dosage Form | Tablet, extended release; Capsule, delayed rel pellets; Tablet, delayed release |
Route | Oral |
Strength | eq 125mg valproic acid; eq 500mg valproic acid; eq 250mg valproic acid |
Market Status | Prescription |
Company | Anchen Pharms; Wockhardt; Upsher Smith; Nu Pharm; Actavis Labs Fl; Teva; Vintage; Aurobindo Pharma; Sun Pharm Inds; Reddys; Lupin; Zydus Pharms Usa; Dr Reddys Labs; Sandoz; Orchid Hlthcare; Mylan; Unichem Labs; Impax Labs |
Anticonvulsants
Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)
Antimanic Agents
Agents that are used to treat bipolar disorders or mania associated with other affective disorders. (See all compounds classified as Antimanic Agents.)
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
GABA Agents
Substances used for their pharmacological actions on GABAergic systems. GABAergic agents include agonists, antagonists, degradation or uptake inhibitors, depleters, precursors, and modulators of receptor function. (See all compounds classified as GABA Agents.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Italy
Brand Name : Depakin
Dosage Form : Valproic Acid+Sodium Valproate 100Mg 30 Joined' Oral Use Rm
Dosage Strength : os grat 30 bust 100 mg modified release
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Italy
Brand Name : Depakin Chrono
Dosage Form : Valproic Acid+Sodium Valproate 300Mg 30 Joined' Oral Use Rp
Dosage Strength : 30 CPR 300 mg prolonged release
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Acidum valproicum; sodium valproas
Brand Name : Depakine Chrono
Dosage Form : Film-Coated Tablets
Dosage Strength : 500mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Acidum valproicum; sodium valproas
Brand Name : Valproate Chrono Sanofi
Dosage Form : Filmtabl
Dosage Strength : 500mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Epilim CR 300
Dosage Form : TAB
Dosage Strength : 300mg
Packaging : 100X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Epilim 100 Crushable
Dosage Form : TAB
Dosage Strength : 100mg
Packaging : 100X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Australia
Brand Name : Epilim EC
Dosage Form :
Dosage Strength :
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Australia
Brand Name : Epilim Liquid
Dosage Form : oral
Dosage Strength : 200 mg/5 mL
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Australia
Brand Name : Valproate Winthrop EC 200
Dosage Form :
Dosage Strength :
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Australia
Brand Name : Epilim EC
Dosage Form :
Dosage Strength :
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
67
PharmaCompass offers a list of Divalproex Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Divalproex Sodium manufacturer or Divalproex Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Divalproex Sodium manufacturer or Divalproex Sodium supplier.
PharmaCompass also assists you with knowing the Divalproex Sodium API Price utilized in the formulation of products. Divalproex Sodium API Price is not always fixed or binding as the Divalproex Sodium Price is obtained through a variety of data sources. The Divalproex Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Valproate Magnesium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Valproate Magnesium, including repackagers and relabelers. The FDA regulates Valproate Magnesium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Valproate Magnesium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Valproate Magnesium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Valproate Magnesium supplier is an individual or a company that provides Valproate Magnesium active pharmaceutical ingredient (API) or Valproate Magnesium finished formulations upon request. The Valproate Magnesium suppliers may include Valproate Magnesium API manufacturers, exporters, distributors and traders.
click here to find a list of Valproate Magnesium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Valproate Magnesium DMF (Drug Master File) is a document detailing the whole manufacturing process of Valproate Magnesium active pharmaceutical ingredient (API) in detail. Different forms of Valproate Magnesium DMFs exist exist since differing nations have different regulations, such as Valproate Magnesium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Valproate Magnesium DMF submitted to regulatory agencies in the US is known as a USDMF. Valproate Magnesium USDMF includes data on Valproate Magnesium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Valproate Magnesium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Valproate Magnesium suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Valproate Magnesium Drug Master File in Japan (Valproate Magnesium JDMF) empowers Valproate Magnesium API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Valproate Magnesium JDMF during the approval evaluation for pharmaceutical products. At the time of Valproate Magnesium JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Valproate Magnesium suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Valproate Magnesium Drug Master File in Korea (Valproate Magnesium KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Valproate Magnesium. The MFDS reviews the Valproate Magnesium KDMF as part of the drug registration process and uses the information provided in the Valproate Magnesium KDMF to evaluate the safety and efficacy of the drug.
After submitting a Valproate Magnesium KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Valproate Magnesium API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Valproate Magnesium suppliers with KDMF on PharmaCompass.
A Valproate Magnesium CEP of the European Pharmacopoeia monograph is often referred to as a Valproate Magnesium Certificate of Suitability (COS). The purpose of a Valproate Magnesium CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Valproate Magnesium EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Valproate Magnesium to their clients by showing that a Valproate Magnesium CEP has been issued for it. The manufacturer submits a Valproate Magnesium CEP (COS) as part of the market authorization procedure, and it takes on the role of a Valproate Magnesium CEP holder for the record. Additionally, the data presented in the Valproate Magnesium CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Valproate Magnesium DMF.
A Valproate Magnesium CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Valproate Magnesium CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Valproate Magnesium suppliers with CEP (COS) on PharmaCompass.
A Valproate Magnesium written confirmation (Valproate Magnesium WC) is an official document issued by a regulatory agency to a Valproate Magnesium manufacturer, verifying that the manufacturing facility of a Valproate Magnesium active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Valproate Magnesium APIs or Valproate Magnesium finished pharmaceutical products to another nation, regulatory agencies frequently require a Valproate Magnesium WC (written confirmation) as part of the regulatory process.
click here to find a list of Valproate Magnesium suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Valproate Magnesium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Valproate Magnesium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Valproate Magnesium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Valproate Magnesium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Valproate Magnesium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Valproate Magnesium suppliers with NDC on PharmaCompass.
Valproate Magnesium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Valproate Magnesium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Valproate Magnesium GMP manufacturer or Valproate Magnesium GMP API supplier for your needs.
A Valproate Magnesium CoA (Certificate of Analysis) is a formal document that attests to Valproate Magnesium's compliance with Valproate Magnesium specifications and serves as a tool for batch-level quality control.
Valproate Magnesium CoA mostly includes findings from lab analyses of a specific batch. For each Valproate Magnesium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Valproate Magnesium may be tested according to a variety of international standards, such as European Pharmacopoeia (Valproate Magnesium EP), Valproate Magnesium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Valproate Magnesium USP).